>_ QFI Terminal
TerminalStocks › PODD

Insulet Corp. (PODD) Stock

Healthcare · Medical - Devices · US
$140.60 -0.67%
Last updated Sep 20, 2026 15:00 UTC

PODD Key Statistics

Market Cap$9.74B
P/E (TTM)26.28
P/S (TTM)3.19
P/B (TTM)6.85
Revenue (TTM)$3.05B
EPS (TTM)$5.35
Dividend Yield
ROE (TTM)26.69%
Net Margin12.29%
Gross Margin71.08%
52W High$354.88
52W Low$126.40
Analyst ViewBuy
Price Target$185.18
Employees5,400
Volume2,495,239

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO: Ashley McEvoy. Company website

PODD — Frequently Asked Questions

What is the PODD stock price today?

Insulet Corp. (PODD) trades at $140.60, down 0.67% on the day, as of Sep 20, 2026 15:00 UTC.

What is Insulet Corp.'s market cap?

Insulet Corp. has a market capitalisation of $9.74B, calculated from the live PODD share price and shares outstanding.

What is the P/E ratio of PODD?

PODD trades at a trailing P/E of 26.28, from earnings per share of $5.35 over the last twelve months.

How much revenue does Insulet Corp. make?

Insulet Corp. generated revenue of $3.05B over the trailing twelve months, which puts the stock at 3.19 times sales.

What is the 52-week range for PODD?

PODD has traded between $126.40 and $354.88 over the past 52 weeks, and the last price is 60.4% below that high.

Is Insulet Corp. profitable?

Yes. Insulet Corp. keeps 12.29% of revenue as net income over the trailing twelve months.

What is the analyst price target for PODD?

Wall Street analysts rate PODD Buy, with an average price target of $185.18, 31.7% above the current price.

What sector is Insulet Corp. in?

Insulet Corp. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.

Who is the CEO of Insulet Corp.?

Ashley McEvoy is the chief executive of Insulet Corp., which employs 5,400 people.

Where can I track PODD in real time?

QFI Terminal shows PODD with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See PODD live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open PODD in Terminal See plans

Medical - Devices stocks

ABT Abbott Laboratories MDT Medtronic plc SYK Stryker Corporation BSX Boston Scientific Corporation GEHC GE HealthCare Technologies Inc. ZBH Zimmer Biomet Holdings, Inc. EW Edwards Lifesciences Corporation SNN Smith & Nephew plc

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.